• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

青少年特发性关节炎治疗进展

Juvenile Idiopathic Arthritis Treatment Updates.

机构信息

Division of Pediatric Rheumatology, Hospital for Special Surgery, Weill Cornell Medicine, 535 E 70th St 5th Floor, New York, NY 10021, USA.

Department of Pediatrics, Division of Rheumatology, University of Alberta, 3-502 ECHA, 11405 87 Ave NW, Edmonton, AB T6G 1C9.

出版信息

Rheum Dis Clin North Am. 2021 Nov;47(4):545-563. doi: 10.1016/j.rdc.2021.07.009. Epub 2021 Sep 2.

DOI:10.1016/j.rdc.2021.07.009
PMID:34635291
Abstract

Juvenile idiopathic arthritis is a group of heterogeneous chronic inflammatory arthropathies occurring in childhood without a known cause. This article discusses the key clinical features of juvenile idiopathic arthritis and treatment updates for oligoarthritis, polyarthritis, enthesitis-related arthritis, psoriatic arthritis, and systemic arthritis. Paradigm changes in management include the earlier use of biologic agents and the introduction of biosimilars and targeted synthetic disease modifying agents like tofacitinib. This review summarizes recent developments while considering potential areas for improvement and study.

摘要

幼年特发性关节炎是一组异质性慢性炎症性关节病,发生于儿童期,病因不明。本文讨论了幼年特发性关节炎的主要临床特征,以及寡关节炎、多关节炎、附着点相关关节炎、银屑病关节炎和全身关节炎的治疗更新。治疗方法的范式转变包括更早地使用生物制剂,以及生物类似药和托法替尼等靶向合成疾病修正药物的引入。本综述总结了最新进展,同时考虑了潜在的改进和研究领域。

相似文献

1
Juvenile Idiopathic Arthritis Treatment Updates.青少年特发性关节炎治疗进展
Rheum Dis Clin North Am. 2021 Nov;47(4):545-563. doi: 10.1016/j.rdc.2021.07.009. Epub 2021 Sep 2.
2
The role of synthetic drugs in the biologic era: therapeutic strategies for treating juvenile idiopathic arthritis.合成药物在生物制剂时代的作用:治疗幼年特发性关节炎的治疗策略
Expert Opin Pharmacother. 2016;17(5):703-14. doi: 10.1517/14656566.2016.1133592. Epub 2016 Jan 13.
3
Treatment of non-systemic juvenile idiopathic arthritis.非系统性幼年特发性关节炎的治疗。
Nat Rev Rheumatol. 2024 Mar;20(3):170-181. doi: 10.1038/s41584-024-01079-8. Epub 2024 Feb 6.
4
Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options.难治性幼年特发性关节炎:当前及未来的治疗选择
Paediatr Drugs. 2016 Apr;18(2):101-8. doi: 10.1007/s40272-016-0164-6.
5
Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis.靶向治疗改善多关节型幼年特发性关节炎的结局研究。
Ann Rheum Dis. 2020 Jul;79(7):969-974. doi: 10.1136/annrheumdis-2019-216843. Epub 2020 Apr 16.
6
Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis.相同但又不同?一项关于阿达木单抗生物类似药在幼年特发性关节炎患者中转换的主题分析。
Pediatr Rheumatol Online J. 2019 Oct 4;17(1):67. doi: 10.1186/s12969-019-0366-x.
7
Biological disease-modifying antirheumatic drugs in juvenile idiopathic arthritis of polyarticular course, enthesitis-related arthritis, and psoriatic arthritis: a consensus statement.生物性改善病情抗风湿药物治疗幼年特发性关节炎多关节型、附着点相关关节炎和银屑病关节炎:共识声明。
Hong Kong Med J. 2020 Feb;26(1):56-65. doi: 10.12809/hkmj198195.
8
Juvenile Idiopathic Arthritis: Oligoarthritis and Polyarthritis.青少年特发性关节炎:少关节炎和多关节炎
Pediatr Clin North Am. 2018 Aug;65(4):657-674. doi: 10.1016/j.pcl.2018.03.005.
9
Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.生物制剂处方趋势和青少年特发性关节炎的结局:荷兰儿童关节炎和生物制剂登记处的结果。
Ann Rheum Dis. 2015 Jul;74(7):1379-86. doi: 10.1136/annrheumdis-2013-204641. Epub 2014 Mar 18.
10
Juvenile Idiopathic Arthritis.幼年特发性关节炎。
Balkan Med J. 2017 Apr 5;34(2):90-101. doi: 10.4274/balkanmedj.2017.0111.

引用本文的文献

1
Literature analysis and implication of biologic therapy for children with non-systemic juvenile idiopathic arthritis in real-world settings.现实环境中生物疗法对非系统性幼年特发性关节炎患儿的文献分析及意义
Intractable Rare Dis Res. 2025 Aug 31;14(3):162-174. doi: 10.5582/irdr.2025.01035.
2
Parents' Satisfaction with Juvenile Idiopathic Arthritis Care: Findings from a Cohort of Italian Children Using the JAMAR Questionnaire.父母对青少年特发性关节炎护理的满意度:来自一组使用JAMAR问卷的意大利儿童的调查结果。
Medicina (Kaunas). 2025 Jun 19;61(6):1115. doi: 10.3390/medicina61061115.
3
[SARS-CoV-2 and post-COVID-19 syndrome in paediatric rheumatology: A scoping review].
[儿童风湿病中的新型冠状病毒2型及新冠后综合征:一项范围综述]
Rev Colomb Reumatol. 2022 Nov 16. doi: 10.1016/j.rcreu.2022.10.003.
4
Comparative efficacy and safety of etanercept and adalimumab in the treatment of polyarticular juvenile idiopathic arthritis.依那西普和阿达木单抗治疗多关节型幼年特发性关节炎的疗效及安全性比较
BMC Pediatr. 2025 Mar 27;25(1):242. doi: 10.1186/s12887-025-05594-9.
5
Health-Related Quality of Life in Juvenile Idiopathic Arthritis: A Systematic Review of Phase III Clinical Trials.青少年特发性关节炎的健康相关生活质量:III期临床试验的系统评价
J Clin Med. 2025 Jan 3;14(1):254. doi: 10.3390/jcm14010254.
6
Adalimumab-induced manic episode in an adolescent with juvenile idiopathic arthritis.阿达木单抗诱发青少年特发性关节炎患者躁狂发作
BMC Psychiatry. 2024 Sep 4;24(1):596. doi: 10.1186/s12888-024-06037-y.
7
Efficacy and safety of gut microbiota-based therapies in autoimmune and rheumatic diseases: a systematic review and meta-analysis of 80 randomized controlled trials.基于肠道菌群的疗法在自身免疫和风湿性疾病中的疗效和安全性:80 项随机对照试验的系统评价和荟萃分析。
BMC Med. 2024 Mar 13;22(1):110. doi: 10.1186/s12916-024-03303-4.
8
Surgical Treatment of Juvenile Idiopathic Arthritis in the Era of Novel Drug Therapies.新型药物治疗时代的幼年特发性关节炎的外科治疗
J Clin Med. 2023 May 11;12(10):3402. doi: 10.3390/jcm12103402.
9
The plasma levels of Dickkopf-1 elevated in patients with Juvenile Idiopathic Arthritis.患者的 Dickkopf-1 血浆水平在幼年特发性关节炎中升高。
Pediatr Res. 2023 Oct;94(4):1349-1354. doi: 10.1038/s41390-023-02637-8. Epub 2023 May 13.
10
Safety and efficacy of probiotic supplementation in 8 types of inflammatory arthritis: A systematic review and meta-analysis of 34 randomized controlled trials.益生菌补充剂在 8 种炎症性关节炎中的安全性和疗效:34 项随机对照试验的系统评价和荟萃分析。
Front Immunol. 2022 Sep 23;13:961325. doi: 10.3389/fimmu.2022.961325. eCollection 2022.